A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in chinese patients with chronic hepatitis B

Esophagus Diseases

Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

Lancet Gastroenterol Hepatol

Takeuchi H, Machida R, Ando M, Tsubosa Y, Kikuchi H, Kawakubo H, Noma K, Ueno M, Tsushima T, Bamba T, Fujita T, Hamai Y, Kakishita T, Daiko H, Koyanagi K, Matsuda S, Kato K, Sasaki K, Kita R, Kitagawa Y, JCOG1409 investigators

doi: 10.1016/S2468-1253(25)00207-9

Gastrointestinal Cancer

Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial

Lancet Gastroenterol Hepatol

Tuynman JB, Yao H, Moolenaar LR, Sietses C, Hompes R, Aigner F, Caycedo-Marulanda A, Chen CC, Deeb M, Doornebosch PG, Feng B, Foo CC, Fürst A, Ito M, de Lacy FB, Leão P, Maykel JA, Muratore A, van Oostendorp SE, Park SC, Pędziwiatr M, Ren M, Seitinger G, Stockmann HBAC, Talsma AK, Türler A, Tong W, Wang Q, Xu Q, Zhang H, van Waesberghe JTM, Ali M, Twisk JWR, Zhang Z, de Lacy AM, Hanna GB, Bonjer HJ, COLOR III Study Group

doi: 10.1016/S2468-1253(26)00022-1

Gallbladder and Biliary Diseases

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU, Cobitz AR, Currie BM, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon JB, Swift B, McLaughlin MM, Levy C, GLISTEN Study Group

doi: 10.1016/S2468-1253(25)00192-X

Hepatitis

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial

J Hepatol

Wedemeyer H, Aleman S, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Lichtman A, Manuilov D, Mercier RC, Arterburn S, Christian-Cox F, Tseng S, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Brunetto MR, Lampertico P

doi: 10.1016/j.jhep.2026.03.046

Hepatitis

Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B study

Am J Gastroenterol

Li J, Liu JK, Chau A, Linden S, Tsai PC, Nozaki A, Vutien P, Uojima H, Toyoda H, Honda T, Trinh H, Abe H, Ishikawa T, Atsukawa M, Watanabe T, Tsuji K, Huang DQ, Takaguchi K, Itobayashi E, Marciano S, Rui F, Ni W, Takahashi H, Chuang WL, Dai CY, Huang JF, Huang CF, Yeh ML, Zhu Y, Itokawa N, Kozuka R, Inoue K, Senoh T, Maeda M, Ito T, Morimoto M, Cheung R, Gadano A, Enomoto M, Tanaka Y, Lim SG, Wu C, Yu ML, Nguyen MH

doi: 10.14309/ajg.0000000000003881

Inflammatory Bowel Disease

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Lancet Gastroenterol Hepatol

Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group

doi: 10.1016/S2468-1253(25)00198-0

Gastritis

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Lancet Gastroenterol Hepatol

Gonsalves NP, Dellon ES, Kliewer KL, Shoda T, Yearout R, Aceves SS, Arva NC, Besse JA, Caldwell JM, Chehade M, Coleman A, Collins MH, Anvari S, Falk GW, Gupta SK, Hiremath G, Katzka DA, Khoury P, Leung J, Menard-Katcher C, Menard-Katcher P, Peterson KA, Pletneva MA, Spergel AKR, Spergel JM, Vaysman T, Wechsler JB, Wright BL, Yang GY, Zhang X, Zhou M, Bansal A, Raphael BP, Radwan A, Maloney J, Martin A, Deniz Y, Furuta GT, Martin LJ, Rothenberg ME, Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Investigators

doi: 10.1016/S2468-1253(26)00116-0

Inflammatory Bowel Disease

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group

doi: 10.1016/S2468-1253(25)00322-X

Gastrointestinal Cancer

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

Lancet

Shen L, Zhang X, Ji K, Lu L, Wang Q, Guan Q, Yan S, Zhou Y, Yang Y, Huo Z, You J, Ba Y, Ye Y, Chen Y, Wang S, Lv G, Zhang J, Hu X, Yang F, Yu H, Li J, Wang Q, Zhu J, Ji J, ASTRUM-006 Study Group

doi: 10.1016/S0140-6736(26)00974-8

Related content

Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial

Long-term effectiveness of tenofovir alafenamide versus entecavir in treatment-naïve chronic hepatitis B: A REAL-B study

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study